Login to Your Account



Inotek to merge into gene therapy-focused Rocket Pharmaceuticals

By Michael Fitzhugh
Staff Writer

Thursday, September 14, 2017

Following the failure of Inotek Pharmaceuticals Corp.'s trabodenoson to move the needle in treating glaucoma, the company has found a new way forward: a proposed merger with New York-based gene therapy startup Rocket Pharmaceuticals Ltd. Led by former Novartis AG cell and gene therapies unit veteran Gaurav Shah, the combined company is developing a pipeline of gene therapies based on lentiviral virus and adeno-associated virus (AAV) platforms, with a focus on treating rare diseases. (See BioWorld, July 11, 2017.)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription